General
Preferred name
GUANFACINE
Synonyms
GUANFACINE HYDROCHLORIDE ()
Intuniv hcl ()
Tenex hcl ()
Connexyn ()
guanfacine, IR, Shire ()
Guanfacine (hydrochloride) ()
Guanfacine, Tenex, Intuniv ()
AKFEN ()
BS 100-141 ()
BS-100-141 ()
ESTULIC ()
GUAFACINE HYDROCHLORIDE ()
GUANFACINE HCL ()
Intuniv ()
SPD503 ()
Tenex ()
Guanfacina ()
NSC-759121 ()
Guanfacine-13C,15N3 ()
P&D ID
PD009591
CAS
29110-47-2
29520-14-7
29110-48-3
1189924-28-4
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
1986
Drug indication
Attention deficit hyperactivity disorder
Hypertension
Primary liver cancer
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Guanfacine hydrochloride is an orally active noradrenergic ¦Á2A agonist and has high selective for the ¦Á2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[1][2][3].
DESCRIPTION Guanfacine is a centrally acting sympatholytic drug acting via activation of α2-adrenoceptors. (GtoPdb)
DESCRIPTION Guanfacine is an orally active noradrenergic ¦Á2A agonist and has high selective for the ¦Á2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[1][2][3].
DESCRIPTION Dopamine agonist (Tocris Bioactive Compound Library)
DESCRIPTION alpha2-Adrenoceptor agonist (LOPAC library)
DESCRIPTION α2A agonist (Tocriscreen Total)
DESCRIPTION Guanfacine hydrochloride (Intuniv) is a centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
40
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Total
ZINC Tool Compounds
External IDs
164
Properties
(calculated by RDKit )
Molecular Weight
245.01
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
1.55
TPSA
78.97
Fraction CSP3
0.11
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
alpha2
MOA
Adrenergic Receptor agonist
Agonist
alpha2-Adrenoceptor Agonists
Target
Adrenergic receptor alpha-2
Adrenergic Receptor
α2A-adrenoceptor
α2B-adrenergic receptor
ADRA2A, ADRA2B, ADRA2C
Primary Target
Adrenergic ?2 Receptors
Member status
member
Indication
hypertension
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Recommended Cell Concentration
None
Source data